XML 37 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1
Collaborations and Other Arrangements (Tables)
6 Months Ended
Jun. 30, 2017
Diabetes Collaboration  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions
The table below summarizes significant regulatory and commercialization events and milestones (received) paid for the compounds included in this collaboration:
 
 
Product Status
 
Milestones
(Deferred) Capitalized (1)
Product Family
 
U.S.
 
Europe
 
Japan
 
Year
Amount
Trajenta (2)
 
Launched 2011
 
Launched 2011
 
Launched 2011
 
2017
$

 
 
 
 
2016

 
 
 
 
Cumulative (4)
446.4

Jardiance (3)
 
Launched 2014
 
Launched 2014
 
Launched 2015
 
2017

 
 
 
 
2016

 
 
 
 
Cumulative (4)
299.5

Basaglar
 
Launched 2016
 
Launched 2015
 
Launched 2015
 
2017

 
 
 
 
2016
(187.5
)
 
 
 
 
Cumulative (4)
(250.0
)

(1) In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as deferred revenue and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales.
(2) Jentadueto is included in the Trajenta family of product results.
(3) Glyxambi and Synjardy are included in the Jardiance family of product results.
(4) The cumulative amount represents the total initial amounts that were (deferred)/capitalized from the start of this collaboration through the end of the reporting period.
Bi Compounds  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions
The following table summarizes our collaboration and other revenue recognized with respect to the Trajenta and Jardiance families of products and net product revenue recognized with respect to Basaglar:
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2017
 
2016
 
2017
 
2016
Trajenta
$
141.9

 
$
121.0

 
$
254.9

 
$
215.4

Jardiance
103.2

 
40.1

 
177.1

 
78.3

Basaglar
86.6

 
16.3

 
132.6

 
27.2

Erbitux  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions
The following table summarizes our revenue recognized with respect to Erbitux:
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2017
 
2016
 
2017
 
2016
Net product revenue
$
134.4

 
$
158.4

 
$
265.7

 
$
299.9

Collaboration and other revenue
24.7

 
22.2

 
47.8

 
48.7

Revenue
$
159.1


$
180.6


$
313.5


$
348.6

Effient  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions
The following table summarizes our revenue recognized with respect to Effient:
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2017
 
2016
 
2017
 
2016
Revenue
$
142.9

 
$
135.1

 
$
270.7

 
$
266.6

Selling, General and Administrative Expenses  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions
The following table summarizes our aggregate amount of marketing, selling, and administrative expense associated with our commission and profit-sharing obligations for the collaborations and other arrangements described in this footnote:
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2017
 
2016
 
2017
 
2016
Marketing, selling, and administrative
$
55.7

 
$
47.3

 
$
102.4

 
$
96.3

Collaborative Arrangement  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions
The following table summarizes our collaboration and other revenue, which is included in revenue in the consolidated condensed statements of operations:
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2017
 
2016
 
2017
 
2016
Collaboration and other revenue
$
294.5

 
$
208.5

 
$
534.9

 
$
390.8